Your browser doesn't support javascript.
loading
Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses
Sebastian Havervall; Ulrika Marking; Nina Greilert-Norin; Max Gordon; Henry Ng; Wanda Christ; Mia Phillipson; Peter Nilsson; Sophia Hober; Kim Blom; Jonas Klingstrom; Sara Mangsbo; Mikael Aberg; Charlotte Thalin.
Affiliation
  • Sebastian Havervall; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Ulrika Marking; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Nina Greilert-Norin; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Max Gordon; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Henry Ng; Department of Medical Cell Biology and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Wanda Christ; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
  • Mia Phillipson; Department of Medical Cell Biology and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Peter Nilsson; Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
  • Sophia Hober; Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
  • Kim Blom; Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden
  • Jonas Klingstrom; Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
  • Sara Mangsbo; Department of Pharmacy and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Mikael Aberg; Department of Medical Sciences, Clinical Chemistry and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Charlotte Thalin; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
Preprint in English | medRxiv | ID: ppmedrxiv-21264948
ABSTRACT
People with previous SARS-CoV-2 infection mount potent immune responses to COVID-19 vaccination, but long-term effects of prior infection on these immune responses are unknown. We investigated the long-term impact of prior SARS-CoV-2 infection on humoral and cellular immune responses in healthcare workers receiving the mRNA BNT162b2 or the adenovirus vectored ChAdOx1 nCoV-19 vaccine. Vaccination with both vaccine platforms resulted in substantially enhanced T cell immune responses, antibody responses to spike and neutralizing antibodies effective against ten SARS-CoV-2 variants following SARS-CoV-2 infection, compared to in naive individuals. The enhanced immune responses sustained over seven months following vaccination. These findings imply that prior infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programs. One-Sentence SummarySARS-CoV-2 infection prior to vaccination leads to substantial and durable increases in immune memory responses.
License
cc_no
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Prognostic study Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Prognostic study Language: English Year: 2021 Document type: Preprint
...